A Phase I Multicentre, Open-label, Dose Escalation Study to Determine the Safety and Preliminary Efficacy of MBS8(1V270) Administered Intravenously to Cancer Patients With Advanced Solid Tumours
Latest Information Update: 24 Oct 2023
At a glance
- Drugs MBS 8 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors MonTa Biosciences
- 18 Oct 2023 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.
- 18 Oct 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2024.
- 21 Mar 2023 According to a MonTa Biosciences media release, the company announce opening of a new clinical site for MonTas phase I clinical trial testing MBS8 in Madtrid